Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil added to pirfenidone in advanced idiopathic pulmonary fibrosis with probable group 3 pulmonary hypertension
NL-OMON43371Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sildenafil, pirfenidone in idiopathic pulmonary fibrosis (IPF), sponsored by Roche. Started Feb 2018; status: active, not recruiting.
02
Drugs
sildenafilpirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON43371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43371.